Recent studies using IGF-I knockout mice demonstrate that IGF binding protein (IGFBP)-5, an important bone formation (BF) regulator, itself is a growth factor with cellular effects not dependent on IGFs. Because IGFBP-5 contains a nuclear localization sequence that mediates transport of IGFBP-5 into the nucleus, we propose that IGFBP-5 interacts with nuclear proteins to affect transcription of genes involved in BF. We, therefore, undertook studies to identify proteins that bind to IGFBP-5 using IGFBP-5 as bait in a yeast two-hybrid screen of a U2 human osteosarcoma cDNA library. Five related clones that interacted strongly with the bait corresponded to the FHL2 gene, which contains four and half LIM domains. Coimmunoprecipitation studies with lysates from U2 cells over-expressing confirmed that interaction between IGFBP-5 and FHL2 occurs in whole cells. In vitro interaction studies revealed that purified FHL2 interacted with IGFBP-5 but not with IGFBP-3, -4 or -6. Northern blot analysis showed that FHL2 was strongly expressed in human osteoblasts.
Introduction
(lacking histidine, leucine, and tryptophan) and incubated for 4-21 days at 30°C. The plates were checked for colonies after 4 days of incubation at 30° C and positive colonies were picked over three weeks time period. Positive colonies were transferred to high stringency minimal selection medium plates (lacking Ade, His, Leu, and Trp, and containing X-α-Gal) plates and incubated at 30 o C until sufficient growth was achieved and colonies turned blue. Positive colonies were maintained on high stringency selection media that select for reporter gene activation.
Isolation of AD-cDNA plasmid
Colonies that activated all of the reporter genes in the AH109 stain were further analyzed.
The AD:cDNA plamid encoding the interacting protein was isolated from yeast cells using a modified Qiagen plasmid prep method obtained from the technical service of Qiagen Inc. The plasmid DNA prepared was then used to transform E. coli (HB101) and colonies containing AD:cDNA plasmid were selected with Ampicillin (50 µg/ml). The Amp R colonies were picked and inoculated into 5 ml LB-Amp medium and grown overnight at 37 o C with shaking. Plasmid DNA was isolated using a Qiagen kit (Qiagen, Valencia, California).
Osteoblast Cell Culture
Normal human osteoblasts were isolated as described (33) from calvaria and rib bone specimens obtained from the Cooperative Human Tissue Network, which is supported by the National Cancer Institute. For the present study, cells isolated from calvaria and rib were grown from frozen stocks made at the second passage and were used at passage 3-4. These cells maintain an osteoblastic phenotype for more than six passages (34) . U-2 Os (HTB-96) and MG63 (CRL-1427) human osteogenic sarcoma cells were from the American Culture Collection (Manassas, VA). SaOs human osteosarcoma cells were low alkaline phosphatase subline developed by Farley et al. (35) . Cells were grown at 37 o C in humidified incubator with 5% CO 2 .
Growth medium consisted of Dulbecco's Modified Eagles Medium (DMEM) (Life Technologies
Inc, Gaithersburg, Maryland), 10% Fe-supplemented newborn calf serum (CS) (Hyclone, Logan, Utah), and 1% antibiotics (Cellgro)
RNA Isolation and Northern analysis
Total RNA from untransformed normal human osteoblasts derived from calvaria and rib and human osteosarcoma cell lines (SaOs-2 and U2) was isolated using the Trizol reagent (GIBCO). 20 µg total RNA was loaded on a 1.2% agarose gel and the gel was blotted using standard techniques (36) after electrophoresis. FHL2 full-length cDNA was randomly 32 Plabeled using a commercial kit (BioLabs, New England) for Northern hybridization. A GAPDH cDNA was used as a control probe. Probes were hybridized at 42 o C in the presence of 50% formamide using standard protocols.
Preparations of nuclear and cytoplasmic extracts
Nuclear and cytoplasmic extracts from normal human calvaria and rib osteoblasts and from U2 cells were prepared as described (37). The nuclear extracts were then used for Western blot analysis using the FHL2 monoclonal anti-body kindly provided by Dr. Muller, University of Freiburg, Freiburg, Germany).
Immunofluorescent microscopy
MG63 cells were plated at 2000 cells/well in 96 well plates in DMEM supplemented with 10% CS. Next day the medium was replaced with serum free medium and cells were incubated for an additional 24 hrs before 10 nM of human recombinant (rh) IGFBP-5 was added. After 48
hrs of incubation in the presence or absence of rhIGFBP-5, cells were fixed, rendered permeable with ethanol and rinsed with PBS. IGFBP-5 protein localization was detected using IGFBP-5 guinea pig polyclonal antibody and fluorescent anti guinea pig secondary antibody. After staining, cells were rinsed three times with PBS, stored in 50% glycerol, and visualized using an Olympus IX70 epi-fluorescence microscope.
Bacterial expression of cDNA clones of interest
A full-length cDNA clone corresponding to the FHL2 was cloned into the expression vector pQE32 (Qiagen) in frame with the 6His tag. The FHL2 coding sequence was amplified by PCR from the selected AD-cDNA plasmid template. We used a primer pair to create BamHI and SalI restriction enzyme sites at 5' and 3' ends, respectively. The forward primer was 5'CGCGGATCCTGACTGAGCGCTT 3' (bold sequence corresponds to BamHI site and underlined sequence correspond to the N-terminus of FHL2), and the reverse primer was 5'ACGCGTCGACAAGTGAACTTGCGGGGTTTTCAGTATCTACG 3' (bold sequence corresponds to the SalI restriction site and underlined sequence corresponds to the pACT2 vector 3' sequence). The PCR product was subsequently purified using QIAXII (Qiagen), digested with BamHI and SalI, and ligated to the vector pQE32. A selected clone was confirmed by DNA sequencing to be in frame with the 6-His tag. The pQE32 expression vector was transformed into E. coli host M15, and expression was induced with isopropyl-β-D-thiogalactopyranoside (IPTG). The rFHL2 was purified according to instructions in the Qiagen Expressionist handbook.
Construction of FHL2 and IGFBP-5-MLV retroviral vectors
In order to over-express the FHL2 and IGFBP-5 cDNAs in bone cells, we constructed a retroviral expression vector. We cloned the FHL2 and IGFBP-5 cDNA coding sequences of 850 and 750 bp, respectively, in place of the β-galactosidase gene in an MLV-based retroviral vector plasmid, pCLSAβ-gal (38) . The FHL2 850 bp cDNA fragment was generated by PCR using a pair of oligonucleotides: the forward primer was 5'ACGCGTCGACATGACTGAGCGCTTT3' and the reverse primer was 5'GCGCGGATCCAATTCAGATGTCTTTCCCAC3'; and the IGFBP-5 cDNA fragment was generated by PCR using the forward primer 5' System (PBS-1, Ciphergen, Fremont, CA) as described previously (43) . Data were collected using laser intensity of 80% and mass calibrated with protein standards (43) .
Results

Verification of the expression of GAL4 DNA binding domain-IGFBP-5 fusion protein in the yeast strain AH109
We Once the expression of our bait in yeast AH109 cells was confirmed, we tested for autoactivation by plating the reporter strain AH109 containing the IGFBP-5 construct on selection medium lacking the amino acids adenine, histidine, and tryptophan. In addition, the selection medium contained X-α-Gal as a color indicator for the expression of the Mel1 reporter gene that encodes α -galactosidase. The results indicated that the IGFBP-5 construct did not auto-activate the reporter genes as no colonies appeared on the test plates.
Identification of proteins that potentially interact with IGFBP-5
We transformed the AH109-IGFBP-5 with an amplified U2 human osteosarcoma cDNA library fused to the GAL activation domain (AD) in the expression vector pACT2. We picked several clones from our initial low stringency screen of the human osteosarcoma cDNA library, which were subsequently transferred to high stringency medium for a second screen. Positive clones were then picked for AD:cDNA plasmid DNA isolation as described in Materials and
Methods.
Sequence analyses of positive AD-cDNA clones
The positive AD-cDNA plasmids that activated all of the three reporter genes in the AH109 strain were isolated and were used to transform the E. coli strain HB101. We then partially sequenced the positive clones and assessed the cDNA sequences using the BLAST program. Five clones matched a known gene sequence in the gene bank (Table 1) plasmids were tested with control plasmids pGADT7-T and pGBKT7-53 to transform the reporter strain, respectively. Hence, the IGFBP-5/FHL2 interaction was specific.
The FHL2 gene is strongly expressed in bone cells
In order to determine if FHL2 is expressed in other bone cell types besides U2 human osteosarcoma cells, total RNA (10 µg per lane) from HBC, HBR, U2, and SaOS-2 human osteosarcoma cells was probed with the EcoRI-XhoI FHL2 cDNA fragment. Northern analysis shows that the FHL2 is expressed in all of the human osteoblast cell types tested. The FHL2 cDNA probe detected a 1.4-1.5 kb band, the size of which is similar to that reported in other cell types ( Figure 3 ).
FHL2 protein localizes in the nucleus and cytoplasm of bone cells
Western blot analysis of nuclear and cytoplasmic extracts from U2, HBC, and HBR were performed using the FHL2 monoclonal antibody. The FHL2 protein was detected in the nuclear and cytoplasmic extracts of both normal human osteoblasts and U2 osteosarcoma cells ( Figure   4A and B). In addition to the 32 kDa band that corresponds to FHL2, high molecular weight bands were seen in the nuclear extracts. These additional bands may represent higher molecular weight forms of FHL2 (dimer or complex of FHL2 with another protein) or other proteins which cross-react with the FHL2 monoclonal antibody used in this study. No band was detected when normal mouse IgG was used for western blotting (data not shown). 
Evidence of IGFBP-5 localization in the nucleus
Recombinant Expression of FHL2
An FHL2 full-length coding sequence PCR product was fused in frame with the 6 His-tag sequences in the expression vector pQE32. The fusion protein was expressed in the E. coli M15
and was purified using Nickel beads. Expression of FHL2 was confirmed by western blot analysis using a His-tag antibody ( Figure 6A ) and the specific FHL2 monoclonal antibody ( Figure 6B ).
FHL2-IGFBP-5 interaction determined by co-immunoprecipitation.
We performed co-immunoprecipitation studies by incubating the FHL2 protein with 125 I labeled IGFBP-5 in the presence of FHL2 monoclonal antibody in test tubes. analysis. Figure 9 shows that IGFBP-5/FHL2 was co-immunoprecipitated by FHL2 antibody in whole U2 cell lysate. These data together with the yeast two-hybrid data provide evidence that the interaction between FHL2 and IGFBP-5 occurs in whole cells following transfection and over-expression of both FHL2 and IGFBP-5.
SELDI ProteinChip analysis
The specificity of FHL2-IGFBP-5 interaction was verified using an alternate technology In this study, co-immunoprecipitation experiments were performed in lysates of U2 cells over-expressing both FHL2 and IGFBP-5. Although these data provide evidence that the interaction between FHL2 and IGFBP-5 could occur in whole cells that are induced to overexpress both of these proteins, they do not prove that these two proteins bind under normal physiological conditions. Further interaction studies using normal human osteoblasts without forced over-expression of either FHL2 or IGFBP-5 are needed to establish that the interaction between FHL2 and IGFBP-5 occurs under physiological conditions.
In order to determine that the FHL2 interaction with IGFBP-5 could occur in other osteoblast cell types, besides U2 human osteosarcoma cells, we evaluated FHL2 expression in untransformed normal human osteoblasts as well as in other human osteosarcoma cell types.
Northern analysis showed that the FHL2 is strongly expressed in human osteoblasts derived from calvaria and rib and in U2 cells. Of the various human osteoblast cell types tested, FHL2
expression was low in SaOs-2 human osteosarcoma cells compared to other human osteoblast cell types. Based on the findings that SaOS-2 cells lack functional p53 and that FHL2
expression is upregulated in cell lines expressing functional p53 and down regulated in cell lines expressing p53 mutants (46), it is possible that p53 is an important regulator of FHL2 expression.
In addition, our data that FHL2 is strongly expressed in normal human osteoblasts argue against the previous conclusion that FHL2 expression is restricted to the cardiovascular system (45-48). + indicates that the transformed AH109 strain grew on high stringency selection medium.
-indicates that the transformed AH109 strain did not grow on high stringency medium. 
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